Why Research Peptides Aren't ANMAT-Approved

ANMAT does not register research peptides because it does not evaluate laboratory supplies: it evaluates medicines intended for human or veterinary use. A peptide catalogued as Research Use Only (RUO) is not a medicine, carries no therapeutic indication, and submits no registration dossier because it belongs to a different legal category. There is no rejected application, and there is no approval pending. The compound and the registration process operate in separate regulatory lanes.

What ANMAT evaluates, and what it does not

The Administración Nacional de Medicamentos, Alimentos y Tecnología Médica has jurisdiction over medicines, foods, and medical devices destined for human or veterinary use. For a medicine to be sold in Argentina, the sponsoring laboratory submits a dossier containing clinical evidence of safety and efficacy, stability data, manufacturing process information, and a proposed package insert. ANMAT evaluates that evidence and, if warranted, grants the registration number authorising sale under the declared indication.

That process exists because there is a patient at the end of the supply chain. Someone is going to ingest, inhale, or inject the compound under a specific therapeutic claim, and the state verifies that the declared benefit exceeded the risk in the study population.

Research peptides have no patient at the end of their supply chain. They have a laboratory. They carry no package insert, no therapeutic indication, and no clinical dossier submitted to obtain one. They do not appear in ANMAT's medicine registry for the same reason an HPLC solvent does not: they are laboratory inputs, and ANMAT does not register laboratory inputs.

The category that does apply: Research Use Only

Research Use Only, abbreviated RUO, is the technical designation identifying compounds supplied exclusively for laboratory research: in vitro studies, cell culture models, and basic research. This category exists in Argentina and in most international regulatory frameworks because legal systems have distinguished for decades between a laboratory reagent and a therapeutic product.

A laboratory reagent can be biologically active. It can have publications on PubMed documenting its effects in animal models or in cell culture. It can be under active study as a drug candidate by pharmaceutical companies. None of those conditions converts it into a medicine. It remains the laboratory supply it was classified as — one that may eventually, if clinical evidence supports it and a company submits the required dossier, become an approved drug in some market.

The literature on retatrutide, MOTS-c, BPC-157, and GHK-Cu documents that earlier stage of the process: in vitro findings, animal model results, and in some cases Phase I or Phase II clinical trials conducted by academic institutions or pharmaceutical sponsors. Those phases do not produce drug approval because they are not the finished product. They are a stage in a sequence that can take more than a decade.

The path from research compound to approved medicine

New drug development follows a documented international sequence: a preclinical stage in laboratory and animal models, Phase I trials in healthy volunteers to evaluate safety, Phase II trials in small groups to establish dose range and early efficacy signals, Phase III trials in large groups comparing the compound against the current standard of care. At the end of that sequence, a company submits the dossier to the regulatory agency of whichever country it wants to enter. In Argentina, that agency is ANMAT.

The average time from the start of compound development to regulatory approval has been documented at eight to fifteen years in the fastest-approving markets. The dropout rate between the start of Phase I and final approval exceeds eighty percent. The cumulative cost for compounds that complete the sequence exceeds one billion dollars.

Most peptides present in the research literature have not completed that sequence. Some have trials in progress: retatrutide is in a Phase III trial coordinated by Eli Lilly, with results published in peer-reviewed journals. Others have solid preclinical evidence without a formally initiated clinical phase. All share the same status with ANMAT: no medicine registration exists because no dossier has been submitted, and no dossier has been submitted because the process enabling it is not yet complete.

What suppliers document instead

A supplier of research materials does not submit a clinical dossier because it is not selling a medicine. What it does provide — and what a receiving laboratory has the right to require — is chemical documentation: a certificate of analysis (CoA) attesting to the compound's identity, its purity as determined by HPLC, and the traceability of that analysis to an accredited external laboratory.

The CoA is not equivalent to a medicine registration and is not presented as one. It documents different things: the purity and identity of the laboratory supply, not therapeutic efficacy in human beings. It is the documentation appropriate to the RUO category.

PeptoClinic's quality page publishes the analyses from Janoshik Analytical, conducted on 13 April 2026. Retatrutide reached 99.893% purity (task 136921). MOTS-c reached 99.669% (task 136923). Both figures are verifiable directly in Janoshik's system using the task number. The verification does not depend on what PeptoClinic states; it depends on what the analytical laboratory published.

What this means for laboratories in Argentina

An Argentine laboratory incorporating peptides into a research program does not look for an ANMAT registration number. It looks at the supplier's CoA. The relevant question is not whether the compound holds a sanitary registration but whether purity is documented by verifiable third-party analysis and whether the batch's traceability chain is complete.

PeptoClinic's catalogue includes compounds at different stages of the research literature, from candidates with ongoing trials to compounds with published preclinical evidence. All are supplied as RUO material with an external laboratory CoA. PeptoClinic handles enquiries from Argentina and prepares the documentation required for import as laboratory reference material. Shipping details by destination are on the shipping page.

For laboratory research only

All material supplied by PeptoClinic is intended exclusively for laboratory research: in vitro studies and basic research settings. It is not a medicine. It is not approved or intended for human or veterinary consumption, diagnosis, or treatment of any condition. No claims regarding these compounds have been evaluated by ANMAT, the FDA, or any equivalent regulatory authority.

PeptoClinic is not a pharmacy, a clinic, or a healthcare provider. Enquiries about protocols or administration in people are not handled.